[Double-Hit Follicular Lymphoma with BCL2 and MYC Translocations]. 2016

Mirei Horiuchi, and Hoyuri Fuseya, and Minako Tsutsumi, and Yoshiki Hayashi, and Kiyoyuki Hagihara, and Hiroshi Kanashima, and Takafumi Nakao, and Yuko Fukushima, and Takeshi Inoue, and Takahisa Yamane
Dept. of Hematology, Osaka City General Hospital.

Double-hit lymphomas are rare tumors that are defined by a chromosomal breakpoint affecting the MYC/8q24 locus in combination with another recurrent breakpoint, mainly a t(14; 18)(q32;q21)involving BCL2. We report a case of a 38-yearold woman with a 2-month history of abdominaldistention. 18F-FDG PET showed multiple positive systemic lymph nodes, positive peritoneum, and multiple positive intra-abdominal masses. Histopathology results of the cervical lymph node were compatible with double-hit follicular lymphoma(Grade 3A)because fluorescence in situ hybridization(FISH)demonstrated both MYC rearrangement and BCL2 gene fusion. She was initially started on R-CHOP(rituximab and doxorubicin, vincristine, cyclophosphamide, and prednisolone), but after one course the regimen was changed to dose-adjusted EPOCH-R(rituximab and doxorubicin, etoposide, vincristine, cyclophosphamide, and prednisolone). However, she showed no response to this chemotherapy regimen or haploidentical stem cell transplantation. The treatment strategy included salvage chemothera- py. An autologous and/or allogeneic hematopoietic transplantation is important for non-responders to DA-EPOCH-R.

UI MeSH Term Description Entries
D008224 Lymphoma, Follicular Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. The nodules resemble to some extent the GERMINAL CENTER of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular center B-LYMPHOCYTES. Brill-Symmers Disease,Follicular Lymphoma,Lymphoma, Giant Follicular,Lymphoma, Nodular,Follicular Large-Cell Lymphoma,Follicular Lymphoma, Giant,Follicular Lymphoma, Grade 1,Follicular Lymphoma, Grade 2,Follicular Lymphoma, Grade 3,Follicular Mixed-Cell Lymphoma,Giant Follicular Lymphoma,Histiocytic Lymphoma, Nodular,Large Lymphoid Lymphoma, Nodular,Large-Cell Lymphoma, Follicular,Lymphocytic Lymphoma, Nodular, Poorly Differentiated,Lymphocytic Lymphoma, Nodular, Poorly-Differentiated,Lymphoma, Follicular Large-Cell,Lymphoma, Follicular, Grade 1,Lymphoma, Follicular, Grade 2,Lymphoma, Follicular, Grade 3,Lymphoma, Follicular, Mixed Cell,Lymphoma, Follicular, Mixed Lymphocytic-Histiocytic,Lymphoma, Follicular, Mixed Small and Large Lymphoid,Lymphoma, Follicular, Small and Large Cleaved Cell,Lymphoma, Follicular, Small and Large Cleaved-Cell,Lymphoma, Histiocytic, Nodular,Lymphoma, Large Cell, Follicular,Lymphoma, Large Lymphoid, Nodular,Lymphoma, Large-Cell, Follicular,Lymphoma, Lymphocytic, Nodular, Poorly Differentiated,Lymphoma, Lymphocytic, Nodular, Poorly-Differentiated,Lymphoma, Mixed-Cell, Follicular,Lymphoma, Nodular, Large Follicular Center Cell,Lymphoma, Nodular, Large Follicular Center-Cell,Lymphoma, Nodular, Mixed Lymphocytic Histiocytic,Lymphoma, Nodular, Mixed Lymphocytic-Histiocytic,Lymphoma, Nodular, Mixed Small and Large Cell,Lymphoma, Small Cleaved Cell, Follicular,Lymphoma, Small Cleaved-Cell, Follicular,Lymphoma, Small Follicular Center-Cell,Lymphoma, Small Lymphoid, Follicular,Mixed-Cell Lymphoma, Follicular,Nodular Large Follicular Center-Cell Lymphoma,Small Cleaved-Cell Lymphoma, Follicular,Small Follicular Center-Cell Lymphoma,Brill Symmers Disease,Disease, Brill-Symmers,Follicular Large Cell Lymphoma,Follicular Large-Cell Lymphomas,Follicular Lymphomas,Follicular Lymphomas, Giant,Follicular Mixed Cell Lymphoma,Follicular Mixed-Cell Lymphomas,Giant Follicular Lymphomas,Histiocytic Lymphomas, Nodular,Large Cell Lymphoma, Follicular,Large-Cell Lymphomas, Follicular,Lymphoma, Follicular Large Cell,Lymphoma, Follicular Mixed-Cell,Lymphoma, Nodular Histiocytic,Lymphoma, Small Follicular Center Cell,Lymphomas, Follicular,Lymphomas, Follicular Large-Cell,Lymphomas, Follicular Mixed-Cell,Lymphomas, Giant Follicular,Lymphomas, Nodular,Lymphomas, Nodular Histiocytic,Mixed Cell Lymphoma, Follicular,Mixed-Cell Lymphomas, Follicular,Nodular Histiocytic Lymphoma,Nodular Histiocytic Lymphomas,Nodular Large Follicular Center Cell Lymphoma,Nodular Lymphoma,Nodular Lymphomas,Small Cleaved Cell Lymphoma, Follicular,Small Follicular Center Cell Lymphoma
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D014178 Translocation, Genetic A type of chromosome aberration characterized by CHROMOSOME BREAKAGE and transfer of the broken-off portion to another location, often to a different chromosome. Chromosomal Translocation,Translocation, Chromosomal,Chromosomal Translocations,Genetic Translocation,Genetic Translocations,Translocations, Chromosomal,Translocations, Genetic
D016271 Proto-Oncogene Proteins c-myc Basic helix-loop-helix transcription factors encoded by the c-myc genes. They are normally involved in nucleic acid metabolism and in mediating the cellular response to growth factors. Elevated and deregulated (constitutive) expression of c-myc proteins can cause tumorigenesis. L-myc Proteins,N-myc Proteins,c-myc Proteins,myc Proto-Oncogene Proteins,p62(c-myc),Proto-Oncogene Products c-myc,Proto-Oncogene Proteins myc,myc Proto-Oncogene Product p62,p62 c-myc,L myc Proteins,N myc Proteins,Proteins myc, Proto-Oncogene,Proto Oncogene Products c myc,Proto Oncogene Proteins c myc,Proto Oncogene Proteins myc,Proto-Oncogene Proteins, myc,c myc Proteins,myc Proto Oncogene Product p62,myc Proto Oncogene Proteins,myc, Proto-Oncogene Proteins,p62 c myc
D017809 Fatal Outcome Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept. Fatal Outcomes,Outcome, Fatal,Outcomes, Fatal
D019253 Proto-Oncogene Proteins c-bcl-2 Membrane proteins encoded by the BCL-2 GENES and serving as potent inhibitors of cell death by APOPTOSIS. The proteins are found on mitochondrial, microsomal, and NUCLEAR MEMBRANE sites within many cell types. Overexpression of bcl-2 proteins, due to a translocation of the gene, is associated with follicular lymphoma. bcl-2 Proto-Oncogene Proteins,c-bcl-2 Proteins,B-Cell Leukemia 2 Family Proteins,BCL2 Family Proteins,BCL2 Proteins,B Cell Leukemia 2 Family Proteins,Family Proteins, BCL2,Proteins, BCL2,Proteins, BCL2 Family,Proto Oncogene Proteins c bcl 2,Proto-Oncogene Proteins, bcl-2,bcl 2 Proto Oncogene Proteins,c bcl 2 Proteins,c-bcl-2, Proto-Oncogene Proteins

Related Publications

Mirei Horiuchi, and Hoyuri Fuseya, and Minako Tsutsumi, and Yoshiki Hayashi, and Kiyoyuki Hagihara, and Hiroshi Kanashima, and Takafumi Nakao, and Yuko Fukushima, and Takeshi Inoue, and Takahisa Yamane
March 2018, Leukemia & lymphoma,
Mirei Horiuchi, and Hoyuri Fuseya, and Minako Tsutsumi, and Yoshiki Hayashi, and Kiyoyuki Hagihara, and Hiroshi Kanashima, and Takafumi Nakao, and Yuko Fukushima, and Takeshi Inoue, and Takahisa Yamane
December 2016, Human pathology,
Mirei Horiuchi, and Hoyuri Fuseya, and Minako Tsutsumi, and Yoshiki Hayashi, and Kiyoyuki Hagihara, and Hiroshi Kanashima, and Takafumi Nakao, and Yuko Fukushima, and Takeshi Inoue, and Takahisa Yamane
March 2021, Translational cancer research,
Mirei Horiuchi, and Hoyuri Fuseya, and Minako Tsutsumi, and Yoshiki Hayashi, and Kiyoyuki Hagihara, and Hiroshi Kanashima, and Takafumi Nakao, and Yuko Fukushima, and Takeshi Inoue, and Takahisa Yamane
January 2014, European journal of haematology,
Mirei Horiuchi, and Hoyuri Fuseya, and Minako Tsutsumi, and Yoshiki Hayashi, and Kiyoyuki Hagihara, and Hiroshi Kanashima, and Takafumi Nakao, and Yuko Fukushima, and Takeshi Inoue, and Takahisa Yamane
September 2013, Advances in anatomic pathology,
Mirei Horiuchi, and Hoyuri Fuseya, and Minako Tsutsumi, and Yoshiki Hayashi, and Kiyoyuki Hagihara, and Hiroshi Kanashima, and Takafumi Nakao, and Yuko Fukushima, and Takeshi Inoue, and Takahisa Yamane
January 2022, Journal of clinical and experimental hematopathology : JCEH,
Mirei Horiuchi, and Hoyuri Fuseya, and Minako Tsutsumi, and Yoshiki Hayashi, and Kiyoyuki Hagihara, and Hiroshi Kanashima, and Takafumi Nakao, and Yuko Fukushima, and Takeshi Inoue, and Takahisa Yamane
February 2015, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc,
Mirei Horiuchi, and Hoyuri Fuseya, and Minako Tsutsumi, and Yoshiki Hayashi, and Kiyoyuki Hagihara, and Hiroshi Kanashima, and Takafumi Nakao, and Yuko Fukushima, and Takeshi Inoue, and Takahisa Yamane
September 2018, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc,
Mirei Horiuchi, and Hoyuri Fuseya, and Minako Tsutsumi, and Yoshiki Hayashi, and Kiyoyuki Hagihara, and Hiroshi Kanashima, and Takafumi Nakao, and Yuko Fukushima, and Takeshi Inoue, and Takahisa Yamane
September 2015, Pathology international,
Mirei Horiuchi, and Hoyuri Fuseya, and Minako Tsutsumi, and Yoshiki Hayashi, and Kiyoyuki Hagihara, and Hiroshi Kanashima, and Takafumi Nakao, and Yuko Fukushima, and Takeshi Inoue, and Takahisa Yamane
March 2023, Blood research,
Copied contents to your clipboard!